#Israel #Tel Aviv #Galmed Pharmaceuticals #Aramchol #NASDAQ GLMD

Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results

Overview
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on therapies for cardiometabolic diseases and potential GI oncological indications. As it moves into the second quarter of 2025, Galmed has shared key updates regarding its financial health and recent developments.

Key Highlights

1. Oncology Research: Galmed recently reported significant findings from studies involving its drug candidate, Aramchol, demonstrating that it enhances the efficacy of Bayer's Regorafenib in gastrointestinal cancer models. This breakthrough positions Galmed as a potential leader in the oncology space, extending its reach beyond core cardiovascular therapies.
2. Strategic Partnerships: The company has signed a term sheet for a novel sublingual formulation of Semaglutide, aiming to diversify its pipeline and improve patient access to vital therapies.
3. Financial Progress: Since the beginning of 2025, Galmed has successfully raised $6.5 million in financing, pushing its cash reserves to approximately $20.1 million. This robust cash position provides the company with a solid foundation to further invest in research and innovation.

Financial Summary

The financial report for the quarter ending March 31, 2025, compared to the same period in 2024, showcases key developments in Galmed's financial trajectory:

• - Cash Reserves: The total cash and cash equivalents rose to about $15.9 million by the end of March 2025, slightly higher than $15.4 million at the end of December 2024. This increase follows additional funding received in May 2025.
• - Net Loss: Galmed recorded a net loss of approximately $1.1 million, or $0.62 per share, an improvement compared to a loss of $1.3 million ($2.76 per share) in Q1 2024. This reduction reflects a decrease in operating expenses and a more focused cost structure.
• - R&D Expenditure: Research and development expenses were stable at around $0.6 million for both Q1 2025 and Q1 2024. This consistency highlights Galmed's commitment to maintaining its developmental momentum.
• - Administrative Costs: General and administrative expenses fell from $0.8 million in 2024 to $0.6 million in 2025, which is indicative of improved operational efficiency and reduced professional service costs.
• - Financial Income: For the first quarter of 2025, Galmed reported net financial income of about $0.2 million, up from $0.1 million the previous year, further bolstering the overall financial health of the company.

Future Prospects

Galmed is not only focused on the development of its core product, Aramchol, but is also strategically expanding its product offerings and indications. The company is poised to advance its product pipeline, particularly in cardio-metabolic indications and innovative candidates. Furthermore, Galmed is navigating the complexities of international regulation and market adoption, ensuring that it remains compliant while pursuing growth opportunities.

Conclusion

Galmed Pharmaceuticals is in a promising position as it moves forward into 2025. With a strong financial foundation, active pipeline development, and positive results in both research and business strategy, the company is set to enhance its presence in the biopharmaceutical industry. Investors and stakeholders will be keenly observing Galmed's progress as it continues to innovate and potentially transform patient care in cardiometabolic and oncological fields.